10% OffFirst Order? Use code
Back to research database
🔬 General ResearchPublished: July 10, 2026

Therapeutic Potential & Cellular Angiogenic Cascade of BPC-157

“BPC-157 (Body Protection Compound-157) is a stable synthetic pentadecapeptide investigated extensively for accelerated musculoskeletal soft tissue healing, VEGFR2-mediated angiogenic sprouting, collagen fibrillogenesis, and systemic gastrointestinal cytoprotection.”

Consult AnalystResearch Database
Peptide vial product illustration

Legal & Laboratory Compliance Notice

FOR IN-VITRO LABORATORY RESEARCH ONLY: This scientific publication is provided strictly for academic and biochemical reference by certified researchers. Materials and compounds referenced are NOT for human consumption, veterinary use, drug manufacture, or direct clinical administration. Statements have not been evaluated by Health Canada or the FDA.

Scientific Research Overview

Abstract & Executive Summary

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid pentadecapeptide derived from a functional sequence within human gastric juice protein BPC. With a molecular mass of 1419.53 Da, BPC-157 is characterized by extraordinary thermodynamic stability, retaining structural integrity across gastric pH gradients (pH 1.0 to 9.0) and resisting degradation by pepsin, trypsin, and general tissue carboxypeptidases.

Unlike traditional growth factors (e.g., PDGF, TGF-β, bFGF) that have short biological half-lives and risk uncontrolled fibrotic scar formation, BPC-157 acts as a master regulator of early physiological repair. It coordinates cell migration, angiogenic collateralization, extracellular matrix (ECM) remodeling, and nitric oxide (NO) homeostasis without promoting abnormal oncogenic proliferation.

+----------------------------------------------------------------------------------------------------+
|                                    BPC-157 PLEIOTROPIC HEALING CASCADE                            |
+------------------------------------+----------------------------------+-----------------------------+
| Vascular / Angiogenesis            | Connective Tissue (Tendon/Muscle)| Gastrointestinal Mucosa     |
| - VEGFR2 pathway activation        | - Egr-1 gene transcription       | - Tight junction assembly   |
| - eNOS/iNOS balance stabilization  | - F-actin cytoskeletal formation | - Counteracts NSAID ulcers  |
| - Rapid collateral vessel bypass   | - Collagen Type I/III synthesis  | - Accelerates ulcer closure |
+------------------------------------+----------------------------------+-----------------------------+

Chemical Structure & Synthesis Parameters

  • Amino Acid Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
  • Single Letter Code: GEPPPGKPADDAGLV
  • Molecular Formula: C62H98N16O22
  • Molecular Weight: 1419.53 g/mol
  • CAS Registry Number: 137525-51-0
  • Isoelectric Point (pI): ~4.12 (acidic character due to aspartate and glutamate residues)
  • Chemical Characteristics: Contains four proline residues (Pro3-Pro4-Pro5 and Pro8), conferring a rigid, folded conformation that resists enzymatic endopeptidase cleavage and stabilizes the molecule in solution.

    • In-Vivo & Preclinical Research Chronology

    Decades of investigations led by Prof. Predrag Sikirić at the University of Zagreb have established BPC-157’s multi-organ regenerative spectrum across standardized animal injury models:

  • Achilles Tendon Transection Models: BPC-157 accelerated functional recovery, enhanced collagen fiber alignment, and restored biomechanical tensile strength to near-uninjured levels within 14-21 days.
  • Medial Collateral Ligament (MCL) Transection: Demonstrated direct bridging of transected ligament gaps with organized collagen bundles rather than disorganized scar tissue.
  • Crushed Muscle / Ischemic Necrosis: Stimulated satellite cell proliferation and restored motor endplate functional transmission.
  • Vascular Occlusion Syndromes: When major vessels (e.g., inferior vena cava or portal vein) were experimentally occluded, BPC-157 rapidly opened collateral shunts, bypassing thrombi and preventing lethal multi-organ congestion.

    • Mechanism of Action

    BPC-157 exerts its biological activity through four interconnected molecular axes:

    1. VEGFR2 Pathway Activation & Angiogenic Collateral Sprouting

    Angiogenesis is the prerequisite for tissue regeneration. BPC-157 directly upregulates and activates Vascular Endothelial Growth Factor Receptor 2 (VEGFR2):

  • Induces rapid VEGFR2 internalizing phosphorylation, triggering the downstream PLCγ-PKC-MAPK/ERK signaling pathway in endothelial cells.
  • Promotes endothelial cell migration, sprouting, and lumen formation.
  • Under severe vascular occlusion or ischemia, BPC-157 accelerates the activation of collateral venous and arterial pathways, re-establishing microvascular tissue perfusion.

    • 2. Early Growth Response-1 (Egr-1) & Collagen Fibrillogenesis

    In tenocytes, fibroblasts, and osteoblasts, BPC-157 stimulates the nuclear transcription factor Early Growth Response-1 (Egr-1):

  • Egr-1 activates transcriptional promoters for Collagen Type I (COL1A1) and Collagen Type III (COL3A1).
  • Promotes the organized parallel deposition of collagen fibers along tension axes rather than chaotic fibrotic cross-linking.
  • Upregulates Growth Hormone Receptor (GHR) density on the surface of tendon fibroblasts, sensitizing healing tissues to circulating systemic anabolic signals.

    • 3. Focal Adhesion Kinase (FAK) & Paxillin Phosphorylation

    Cellular motility is critical for wound closure. BPC-157 stimulates the FAK-Paxillin signaling axis:

  • Induces phosphorylation of Focal Adhesion Kinase (Tyr397) and Paxillin (Tyr118), reorganizing the intracellular F-actin cytoskeleton.
  • Enhances the formation of filopodia and lamellipodia, accelerating the migratory velocity of fibroblasts into the wound bed.

    • 4. Bimodal Nitric Oxide (NO) System Homeostasis

    BPC-157 acts as an endogenous modulator of the nitric oxide synthase (NOS) network:

  • Under Ischemia / Vasoconstriction: Upregulates endothelial NOS (eNOS), releasing vaso-relaxing NO to restore capillary lumen diameter and blood flow.
  • Under Endotoxic / Inflammatory Shock: Suppresses excessive inducible NOS (iNOS) over-activation, preventing toxic peroxynitrite radical accumulation and hypotension.

    • Key Study Highlights

    ✓

    VEGFR2 Angiogenesis

    Drives endothelial sprouting and rapid collateral microvascular bypass formation.

    ✓

    Tenocyte Collagen Matrix

    Upregulates Egr-1 and collagen Type I/III synthesis, restoring tendon tensile strength.

    ✓

    Gastric Mucosal Stability

    Demonstrates high stability in human gastric juice, healing NSAID and ethanol-induced ulcers.

    ✓

    Dual NOS Modulation

    Regulates eNOS and iNOS balance, buffering against both ischemic and hyper-inflammatory damage.

    Scientific FAQs

    BPC-157 contains a proline-rich core (Pro3-Pro4-Pro5 and Pro8) that provides high conformational rigidity. It does not degrade in human gastric juice or acidic buffers (pH 1-9) for hours, unlike fragile growth factors like bFGF or VEGF.
    Research indicates BPC-157 promotes organized collagen Type I alignment along mechanical tension lines rather than disorganized scar tissue (fibrosis), resulting in superior structural tensile strength recovery.
    Molecular Formula: C62H98N16O22, Molecular Weight: 1419.53 g/mol, CAS Number: 137525-51-0.
    Reconstitute with sterile Bacteriostatic Water (0.9% benzyl alcohol). Store lyophilized vials at -20°C. Once reconstituted, store at 2°C to 8°C in a dark environment and utilize within 28 days for optimal analytical purity.

    References

    1. Sikiric P. et al (2020).
      Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease and healing
      Curr Pharm Des, 26(25):2991-3007
      View Research Paper ↗
    2. Chang C.H. et al (2014).
      Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts
      J Orthop Res, 32(3):478-485
      View Research Paper ↗
    3. Vukojevic J. et al (2018).
      Rat inferior caval vein occlusion: BPC 157 rapidly bypasses occlusion and resolves thrombosis
      Curr Pharm Des, 24(18):1972-1983
      View Research Paper ↗

    Procure Research Reference Materials

    Access laboratory-grade reference compounds with verified batch HPLC purity reports and sterility documentation.

    View Compound Specifications

    Literature Inquiries

    Have questions about the pre-clinical citations or chemical parameters detailed in this research? Connect with our analytical representatives.

    Contact Researchers